APOC3 and familial partial lipodystrophy: In this proof-of-concept study in patients with genetic or clinical diagnosis of FPLD, treatment with the novel therapeutic vupanorsen targeting ANGPTL3, resulted in a robust reduction in fasting triglycerides associated with a reduction in ANGPTL3, VLDL-C, non-HDL-C, and apoC-III levels.